Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03076437 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | completed | Phase 1 / Phase 2 | 28 | Shenzhen Institute for Innovation and Translational MedicineOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT01088048 | Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 1 | 241 | Gilead Sciences |
| 1 |
| Mar 18, 2021 |
| clinicaltrials |
| NCT01659255 | Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL | completed | Phase 1 | 90 | Gilead SciencesINDUSTRY | 2 | Mar 16, 2021 | clinicaltrials |
| NCT03081780 | Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML | completed | Phase 1 | 6 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT01440920 | A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients | completed | Phase 1 | 9 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 8, 2021 | clinicaltrials |
| NCT02293993 | Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia | completed | Phase 1 | 21 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 5, 2021 | clinicaltrials |
| NCT00620633 | Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation | completed | Phase 1 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT01475370 | Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001) | completed | Phase 1 | 18 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 2, 2021 | clinicaltrials |
| NCT00306202 | Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia | completed | Phase 1 | 63 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 26, 2021 | clinicaltrials |
| NCT03197714 | Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia | completed | Phase 1 | 9 | Hospital Universitario 12 de OctubreOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT02948283 | Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia | completed | Phase 1 | 3 | City of Hope Medical CenterOTHER | 1 | Feb 12, 2021 | clinicaltrials |
| NCT00637052 | A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia | completed | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 1 | Feb 8, 2021 | clinicaltrials |
| NCT01445080 | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Feb 2, 2021 | clinicaltrials |
| NCT03289455 | CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)(AMELIA) | completed | Phase 1 / Phase 2 | 23 | Autolus LimitedINDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT01713582 | A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) | completed | Phase 1 | 141 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT02423915 | Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | completed | Phase 1 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT00621244 | A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies | completed | Phase 1 / Phase 2 | 175 | Novartis PharmaceuticalsINDUSTRY | 3 | Jan 5, 2021 | clinicaltrials |
| NCT01702064 | Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients | completed | Phase 1 | 11 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT01474681 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 27 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 30, 2020 | clinicaltrials |
| NCT01077544 | A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 | 15 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 29, 2020 | clinicaltrials |
| NCT00831766 | Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 51 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT00093600 | PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 69 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT01055483 | A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 | 59 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT01242774 | Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 46 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 19, 2020 | clinicaltrials |
| NCT01613976 | A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients | completed | Phase 1 | 10 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01223898 | To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib | completed | Phase 1 | 19 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 9, 2020 | clinicaltrials |
| NCT01456676 | Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy | completed | Phase 1 | 11 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 9, 2020 | clinicaltrials |
| NCT00384228 | A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL | completed | Phase 1 / Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01279473 | Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study) | completed | Phase 1 / Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT02046122 | Adoptive Transfer of Haplo-identical DLI for AML and MDS | completed | Phase 1 / Phase 2 | 19 | Duke UniversityOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT02900716 | Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas | completed | Phase 1 | 48 | Zhejiang DTRM BiopharmaINDUSTRY | 1 | Nov 27, 2020 | clinicaltrials |
| NCT02750995 | Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML(AZACTA) | completed | Phase 1 | 5 | Daniel El FassiOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT02504359 | Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | completed | Phase 1 | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT02580552 | Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL | completed | Phase 1 | 66 | miRagen Therapeutics, Inc.INDUSTRY | 1 | Nov 23, 2020 | clinicaltrials |
| NCT02799147 | GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia | completed | Phase 1 / Phase 2 | 27 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT01943682 | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | completed | Phase 1 | 27 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT01914484 | Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia | completed | Phase 1 / Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT00301093 | Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT01816230 | Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | completed | Phase 1 / Phase 2 | 36 | Gamida Cell ltdINDUSTRY | 5 | Oct 22, 2020 | clinicaltrials |
| NCT00821249 | A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 55 | PfizerINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00822770 | Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin | completed | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02029950 | Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2020 | clinicaltrials |
| NCT01246622 | Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 32 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT03232619 | CD19-CART Treatment for ALL | completed | Phase 1 / Phase 2 | 4 | Bioray LaboratoriesINDUSTRY | 1 | Sep 22, 2020 | clinicaltrials |
| NCT00442130 | Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination | completed | Phase 1 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT00809250 | Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation | completed | Phase 1 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02928523 | PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients(ODYSSEE) | completed | Phase 1 / Phase 2 | 20 | MaaT PharmaINDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03097770 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | completed | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Sep 2, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Mar 19, 2021source: clinicaltrials